FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2012161505> ?p ?o ?g. }

• W2012161505 endingPage "454" @default.
• W2012161505 startingPage "448" @default.
• W2012161505 abstract "Introduction. Gemcitabine based regimens have been widely used in patients with advanced cholangiocarcinoma (CC), but no standard therapy exists. In this study we aimed to find the maximally tolerated dose (MTD) of a two-week schedule of fixed dose rate (FDR) gemcitabine (G), oxaliplatin (O) and capecitabine (C), and evaluate the safety and efficacy of this regimen in patients with advanced cholangiocarcinoma (CC). Methods. In the Phase I part of the study a dose-escalation schedule of FDR G, O and C, administered every two weeks, was performed in patients with solid tumours and no other treatments or advanced CC. In the Phase II part response rate, toxicity, progression-free survival (PFS) and overall survival was evaluated in patients with newly diagnosed advanced CC. Results. Thirty-six patients entered the Phase I part and G 1 000 mg/m2 day 1 and 15, O 60 mg/m2 day 1 and 15, and C 1 000 mg/m2 BID day 1–7 and day 15–21 were established as MTD. In the Phase II part, 41 patients with advanced CC were included. Overall response rate was 34% and 51% had stable disease, resulting in a clinical benefit rate of 85%. Grade III and IV adverse events were rare. Median survival was 12.5 months (95% CI 9.2–15.9) and median progression-free survival (PFS) was 6.9 months (95% CI 5.1–8.6). Conclusions. This outpatient regimen was very feasible with significant activity and a favourable safety profile. Further studies will explore this combination with addition of newer targeted agents." @default.
• W2012161505 created "2016-06-24" @default.
• W2012161505 creator A5035087900 @default.
• W2012161505 creator A5040078542 @default.
• W2012161505 creator A5040739416 @default.
• W2012161505 creator A5048866467 @default.
• W2012161505 creator A5077199450 @default.
• W2012161505 creator A5082627841 @default.
• W2012161505 date "2010-07-29" @default.
• W2012161505 modified "2023-10-14" @default.
• W2012161505 title "A Phase I–II dose escalation study of fixed-dose rate gemcitabine, oxaliplatin and capecitabine every two weeks in advanced cholangiocarcinomas" @default.
• W2012161505 cites W1908187732 @default.
• W2012161505 cites W1965728914 @default.
• W2012161505 cites W1968773418 @default.
• W2012161505 cites W1973648602 @default.
• W2012161505 cites W1983137139 @default.
• W2012161505 cites W1989145928 @default.
• W2012161505 cites W1992110951 @default.
• W2012161505 cites W2004869577 @default.
• W2012161505 cites W2007700830 @default.
• W2012161505 cites W2025769688 @default.
• W2012161505 cites W2060221454 @default.
• W2012161505 cites W2062628269 @default.
• W2012161505 cites W2063515380 @default.
• W2012161505 cites W2073346844 @default.
• W2012161505 cites W2094501197 @default.
• W2012161505 cites W2096888043 @default.
• W2012161505 cites W2101397109 @default.
• W2012161505 cites W2115261608 @default.
• W2012161505 cites W2118520585 @default.
• W2012161505 cites W2120848645 @default.
• W2012161505 cites W2124410855 @default.
• W2012161505 cites W2135103642 @default.
• W2012161505 cites W2138485537 @default.
• W2012161505 cites W2139947970 @default.
• W2012161505 cites W2145139896 @default.
• W2012161505 cites W2169946736 @default.
• W2012161505 cites W2319550695 @default.
• W2012161505 cites W4211234270 @default.
• W2012161505 cites W4240420301 @default.
• W2012161505 doi "https://doi.org/10.3109/0284186x.2010.500300" @default.
• W2012161505 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20670085" @default.
• W2012161505 hasPublicationYear "2010" @default.
• W2012161505 type Work @default.
• W2012161505 sameAs 2012161505 @default.
• W2012161505 citedByCount "16" @default.
• W2012161505 countsByYear W20121615052012 @default.
• W2012161505 countsByYear W20121615052013 @default.
• W2012161505 countsByYear W20121615052014 @default.
• W2012161505 countsByYear W20121615052015 @default.
• W2012161505 countsByYear W20121615052016 @default.
• W2012161505 countsByYear W20121615052017 @default.
• W2012161505 countsByYear W20121615052018 @default.
• W2012161505 countsByYear W20121615052019 @default.
• W2012161505 countsByYear W20121615052020 @default.
• W2012161505 countsByYear W20121615052021 @default.
• W2012161505 crossrefType "journal-article" @default.
• W2012161505 hasAuthorship W2012161505A5035087900 @default.
• W2012161505 hasAuthorship W2012161505A5040078542 @default.
• W2012161505 hasAuthorship W2012161505A5040739416 @default.
• W2012161505 hasAuthorship W2012161505A5048866467 @default.
• W2012161505 hasAuthorship W2012161505A5077199450 @default.
• W2012161505 hasAuthorship W2012161505A5082627841 @default.
• W2012161505 hasBestOaLocation W20121615051 @default.
• W2012161505 hasConcept C121608353 @default.
• W2012161505 hasConcept C126322002 @default.
• W2012161505 hasConcept C141071460 @default.
• W2012161505 hasConcept C143998085 @default.
• W2012161505 hasConcept C197934379 @default.
• W2012161505 hasConcept C2776694085 @default.
• W2012161505 hasConcept C2777844706 @default.
• W2012161505 hasConcept C2777909004 @default.
• W2012161505 hasConcept C2780258809 @default.
• W2012161505 hasConcept C2780962732 @default.
• W2012161505 hasConcept C2781413609 @default.
• W2012161505 hasConcept C29730261 @default.
• W2012161505 hasConcept C31760486 @default.
• W2012161505 hasConcept C526805850 @default.
• W2012161505 hasConcept C71924100 @default.
• W2012161505 hasConcept C90924648 @default.
• W2012161505 hasConceptScore W2012161505C121608353 @default.
• W2012161505 hasConceptScore W2012161505C126322002 @default.
• W2012161505 hasConceptScore W2012161505C141071460 @default.
• W2012161505 hasConceptScore W2012161505C143998085 @default.
• W2012161505 hasConceptScore W2012161505C197934379 @default.
• W2012161505 hasConceptScore W2012161505C2776694085 @default.
• W2012161505 hasConceptScore W2012161505C2777844706 @default.
• W2012161505 hasConceptScore W2012161505C2777909004 @default.
• W2012161505 hasConceptScore W2012161505C2780258809 @default.
• W2012161505 hasConceptScore W2012161505C2780962732 @default.
• W2012161505 hasConceptScore W2012161505C2781413609 @default.
• W2012161505 hasConceptScore W2012161505C29730261 @default.
• W2012161505 hasConceptScore W2012161505C31760486 @default.
• W2012161505 hasConceptScore W2012161505C526805850 @default.
• W2012161505 hasConceptScore W2012161505C71924100 @default.
• W2012161505 hasConceptScore W2012161505C90924648 @default.
• W2012161505 hasIssue "3" @default.
• W2012161505 hasLocation W20121615051 @default.

• next